Metagenomi Announces Board Changes and Shareholder Meeting Results
I'm LongbridgeAI, I can summarize articles.Metagenomi, Inc. (MGX) announced that board member Brian C. Thomas resigned effective June 9, 2026, without disagreement. At its virtual annual meeting, shareholders elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as the independent auditor. The company highlighted strong shareholder support for its governance framework during a critical development phase in genetic medicines.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
An announcement from Metagenomi, Inc. ( (MGX) ) is now available.
On June 9, 2026, Metagenomi Therapeutics, Inc. announced that board member Brian C. Thomas, Ph.D. resigned from the board effective the same day, with the company emphasizing that his departure did not stem from any disagreement over its operations, policies or practices and expressing gratitude for his service. Also on June 9, 2026, at its virtual annual meeting of stockholders, the company reported that shareholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors to serve until the 2029 annual meeting and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing continuity in its board composition and audit oversight.
The company noted that 19,116,207 shares of common stock were present or represented by proxy at the meeting, establishing a quorum out of 37,647,057 shares entitled to vote as of the April 13, 2026 record date. Voting results showed solid support for both director nominees and the auditor ratification, signaling shareholder backing for Metagenomi’s governance framework and financial reporting arrangements during a critical phase of its development in the genetic medicines space.
The most recent analyst rating on (MGX) stock is a Buy
with a $7.00 price target.
To see the full list of analyst forecasts on Metagenomi, Inc. stock,
see the MGX Stock Forecast page.
Spark’s Take on MGX Stock
According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.
The score is held down primarily by very weak financial performance (large, persistent losses and heavy negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Offsetting this partially are positive corporate updates, including stated cash runway through Q4 2027 and progress toward upcoming regulatory milestones, but valuation remains unattractive in traditional terms due to ongoing unprofitability.
To see Spark’s full report on MGX stock,
click here.
More about Metagenomi, Inc.
Metagenomi Therapeutics, Inc. operates in the biotechnology and biopharmaceutical industry, developing genetic medicines that leverage gene-editing technologies to treat serious diseases. The company focuses on advancing a pipeline of therapeutics aimed at addressing unmet medical needs, positioning itself within the competitive genomic medicine and precision therapeutics market.
Average Trading Volume: 191,553
Technical Sentiment Signal: Sell
Current Market Cap: $46.31M
For a thorough assessment of MGX stock, go to TipRanks’ Stock Analysis page.